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The use of β-blockers (BB) in heart failure (HF) has been considered a contradiction
for many years. Considering HF simply as a state of inadequate systolic function,
BB were contraindicated because of their negative effects on myocardial contractility.
Nevertheless, evidence collected in the past years have suggested that additional
mechanisms, such as compensatory neuro-humoral hyperactivation or inflammation, could
participate in the pathogenesis of this complex disease. Indeed, chronic activation of the
sympathetic nervous system, although initially compensating the reduced cardiac output
from the failing heart, increases myocardial oxygen demand, ischemia and oxidative stress;
moreover, high catecholamine levels induce peripheral vasoconstriction and increase both
cardiac pre- and after-load, thus determining additional stress to the cardiac muscle (1).
As a consequence of such a different view of the pathogenic mechanisms of HF, the
efficacy of BB in the treatment of HF has been investigated in numerous clinical trials.
Results from these trials highlighted BB as valid therapeutic tools in HF, providing rational
basis for their inclusion in many HF treatment guidelines. However, controversy still exists
about their use, in particular with regards to the selection of specific molecules, since
BB differ in terms of adrenergic β-receptors selectivity, adjunctive effects on α-receptors,
and effects on reactive oxygen species and inflammatory cytokines production. Further
concerns about the heterogeneity in the response to BB, as well as the use in specific
patients, are matter of debate among clinicians. In this review, we will recapitulate
the pharmacological properties and the classification of BB, and the alteration of the
adrenergic system occurring during HF that provide a rationale for their use; we will also
focus on the possible molecular mechanisms, such as genetic polymorphisms, underlying
the different efficacy of molecules belonging to this class.
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INTRODUCTION
The use of β-blockers (BB) in heart failure (HF) has been con-
sidered a contradiction for many years. Considering HF simply
as a state of inadequate systolic function, BB were contraindi-
cated because of their negative effects on myocardial contrac-
tility. Nevertheless, evidence collected in the past years have
suggested that additional mechanisms, such as compensatory
neuro-humoral hyperactivation or inflammation, could partici-
pate in the pathogenesis of this complex disease. Indeed, chronic
activation of the sympathetic nervous system, although initially
compensating the reduced cardiac output from the failing heart,
increases myocardial oxygen demand, ischemia and oxidative
stress; moreover, high catecholamine levels induce peripheral
vasoconstriction and increase both cardiac pre- and after-load,
thus determining additional stress to the cardiac muscle (Kubon
et al., 2011). As a consequence of such a different view of the
pathogenic mechanisms of HF, the efficacy of BB in the treatment
of HF has been investigated in numerous clinical trials. Results
from these trials highlighted BB as valid therapeutic tools in HF,
providing rational basis for their inclusion in many HF treatment
guidelines. However, controversy still exists about their use, in
particular with regards to the selection of specific molecules, since
BB differ in terms of adrenergic β-receptors (β-ARs) selectivity,
adjunctive effects on α-receptors, and effects on reactive oxygen
species and inflammatory cytokines production. Further con-
cerns about the heterogeneity in the response to BB, as well as the
use in specific patients, are matter of debate among clinicians. In
this review, we will recapitulate the pharmacological properties
and the classification of BB, and the alteration of the adrener-
gic system occurring during HF that provide a rationale for their
use; we will also focus on the possible molecular mechanisms,
such as genetic polymorphisms, underlying the different efficacy
of molecules belonging to this class.
HISTORY, STRUCTURE AND CLASSIFICATION OF
ADRENERGIC BETA RECEPTORS
To date, three subtypes of β-receptors (β1-AR, β2-AR and β3-AR)
have been identified; the existence of a fourth subtype, called
β4, has been proposed to explain the sympathomimetic effects
of some atypical β-agonists (such as CGP-12177) known to be
inactive on the “classical” β-receptors; however recent evidence
suggest that the putative β4 receptor is more likely a novel
functional state of β1 receptor (Granneman, 2001).
β-ARs display peculiar tissue distribution and pharmaco-
logical properties: β1 is the “cardiac” receptor, while β2 is
expressed predominantly in smooth muscle cells, and β3 in
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the adipose tissue. Structurally, β-ARs belong to the fam-
ily of G protein-coupled receptors, with seven transmembrane
domains, an extracellular N-terminal region, and an intracel-
lular C-terminus. Although, in the heart, β1 is the predomi-
nant AR subtype, cardiac cells express also β2 and, to a less
extent, β3, with quantitative differences depending on age and
pathological conditions. In particular, β-AR population of the
non-failing heart is composed of β1 and β2, in a ratio of 8:2;
however, in both ageing and HF, the proportion of β1 sub-
types decreases due to mRNA down-regulation, while levels of
β2-AR remain stable, thus achieving a 1:1 ratio of β1- and β2-
ARs (Lohse et al., 2003). In the heart, stimulation of β-ARs
pathway leads to the activation of the Gs protein, with conse-
quent stimulation of the adenylate cyclase, increase in intracel-
lular cAMP, and protein kinase A-dependent phosphorylation
and modulation of the activity of important proteins involved
in myocardial contractility, such as L-type Ca2+ channels, tro-
ponin I and sarcoplasmic reticular Ca2+/ATPase inhibitory
protein (Wachter and Gilbert, 2012). Moreover, through the
βγ-subunits of the heterotrimeric G-protein, β-AR stimulation
activates members of the G-protein receptors kinase family,
named βARK (βγ-AR kinase) or GRK2 (G-protein receptor
kinase 2), which are a primary mechanism of self-regulation of
adrenergic stimulation. Indeed, by phosphorylating residues in
the C-terminal region of the receptor, GRK2 induce the bind-
ing of protein such as β-arrestin to the receptor, thus caus-
ing its uncoupling from the Gs protein and its transductional
pathways; moreover, GRK2-induced phosphorylation also cause
an increase in the affinity of β-AR for the inhibitory G pro-
tein Gi, thus accelerating receptor desensitization (Rengo et al.,
2012b).
Although the main intracellular pathway activated by β-ARs
is Gs signaling, it has been demonstrated that stimulation of β-
ARs can also activate Gi proteins, MAP kinases and other proteins
involved in the control of cell cycle and apoptosis (Bogoyevitch
et al., 1996), in a subtype-specific manner, thus differentially
influencing cardiomyocytes fate. These evidence suggest that
modulation of β-ARs can impact cardiac pathophysiology in dif-
ferent and multiple ways, well beyond than simply controlling
heart mechanics.
MOLECULAR MECHANISMS UNDERLYING β ADRENERGIC
SYSTEM DYSREGULATION IN HF AND THE EFFICACY OF
β-BLOCKERS
HF is associated to dramatic changes in neurohormonal balance.
To compensate the reduced cardiac output, an increased activity
of the adrenergic nervous system (ANS), as well as an activa-
tion of the Renin-Angiotensin-Aldosterone System (RAAS) occur.
As a consequence of ANS hyperactivity, norepinephrine and
epinephrine plasma levels increase, due to adrenal gland secretion
and adrenergic terminals spillover, thus leading to chronic sympa-
thetic stimulation of the heart. Such stimulation of cardiac β-ARs
increases oxygen demand andmyocardial work, thus contributing
to cardiac muscle stress. In adult rat myocytes, β1-AR mediates
apoptotic signaling, whereas the β2 subtype seems to stimu-
late antiapoptotic pathways coupling to the inhibitory G protein
(Gi) (Bristow, 2000). Stimulation of renal iuxtaglomerular β1-AR
can also activate RAAS, thus causing an increase in angiotensin-
related cardiac remodeling and apoptosis (Lymperopoulos et al.,
2013). Negative effects of ARs hyperactivity are also recapitulated
by transgenic mouse models; indeed, transgenic mice overex-
pressing β1-AR (Engelhardt et al., 1999) or cardiac Gαs (Iwase
et al., 1996) show a cardiomyopathy with ventricular dilata-
tion and systolic dysfunction; by contrast, cardiac overexpression
of β2-AR improves contractility in the healthy heart (Akhter
et al., 1997). Chronic ANS activation is also responsible for
the selective down-regulation of β1-AR and for the functional
uncoupling of both β1- and β2-ARs from their intracellular cou-
pling mechanisms; these events are determined by activation
of GRKs, particularly GRK2. Indeed, it has been demonstrated
that, in chronic HF, GRK2 is up-regulated in cardiomyocytes,
thus leading to a reduced responsiveness of the cardiac mus-
cle to catecholamines stimulation (Rengo et al., 2011). GRK2-
induced ARs uncoupling and down-regulation also occur in the
adrenal gland, where the inhibitory feedback on catecholamine
release mediated by inhibitory α2-ARs is reduced, thus deter-
mining an increase of circulating epinephrine (Lymperopoulos
et al., 2007). GRK2 inhibition by a small peptide (βARK ct)
increases cardiac contractility, normalizes neurohormonal axis
activity, and improves survival in several animal models of HF
(Rockman et al., 1998).
The molecular evidence here briefly reviewed have rein-
forced the hypothesis that the changes in the ANS during
HF are not merely adaptive, but rather play a direct patho-
genetic role, opening novel avenues to interpret the efficacy of
drugs acting by blocking β-ARs in HF. In fact, BB might exert
beneficial effects well beyond those exerted in cardiac muscle
(limiting AR decrease in number and functional desensitiza-
tion) (Iaccarino et al., 1998), such as counteracting some aber-
rant maladaptive responses of ANS and RAAS neurohormonal
systems occurring in HF. Indeed, it has been recently demon-
strated that bisoprolol normalized the adrenal catecholamine
production by reducing GRK2 levels, thus restoring the nega-
tive feedback on epinephrine release exerted by α2-AR (Rengo
et al., 2012a). In addition, atenolol and bisoprolol treatment
have been also shown to improve myocardial perfusion by
enhancing neoangiogenesis in the failing heart, via activation
of VEGF signaling pathway (Dedkov et al., 2005; Rengo et al.,
2013).
BETA-BLOCKERS: CLASSIFICATION AND PHARMACOLOGY
BB are a wide and heterogeneous group of molecules acting
as competitive and reversible antagonists of β-ARs. In addi-
tion to their ability to block β-ARs-signaling, BB show a variety
of adjunctive actions that are often used as criteria for their
classification (see Table 1).
BB can be classified according to:
β1-AR-SELECTIVITY
Propranolol and timolol are the prototypical non-selective, “first
generation” BB, showing the same affinity for both β1 and β2 sub-
types. Subsequent research, aiming to find cardioselective drugs,
led to the synthesis of molecules such as atenolol, bisoprolol and
metoprolol, preferentially blocking “cardiac” β1-AR.
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Table 1 | Main pharmacological properties of BB.
Drug Selectivity ISA α–AR blockade Membrane-stabilizing
activity
Bioavailability (%) Half-life (hrs)
β non-selective
Propranolol 0 0 0 ++ 25 3–5
Nadolol 0 0 0 0 35 10–20
Timolol 0 0 0 0 50 3–5
Pindolol 0 ++ 0 ± 75 3–4
Labetalol 0 + + ± 20 4–6
Carvedilol 0 0 + 0 30 7–10
β1-selective
Metoprolol ++ 0 0 ± 40 3–4
Atenolol ++ 0 0 0 50 5–8
Esmolol ++ 0 0 0 − 0.13
Acebutolol + + 0 + 40 8–12 (diacetolol)
Bisoprolol ++ 0 0 0 90 9–12
Nebivolol ++ 0 0 0 12–96* 10–30*
Abbreviations: ISA: intrinsic sympathomimetic activity; α-AR: alpha adrenergic receptor.
*Depending on CYP polymorphisms.
Data are mainly from refs. (Rockman et al., 1998) and (Goodman and Gilman’s, 2011).
α-AR-ANTAGONISM AND VASODILATOR ACTIVITY
Labetalol, bucindolol and carvedilol also act as α1-AR-
antagonists. This pharmacological effect is particularly important
in HF, since the peripheral vasodilatation induced by α1-AR
blockade decreases both pre- and after-loads, thus reducing
myocardial oxygen consumption and work. Other BB such as
nebivolol, although not provided of α1-AR antagonism, show
marked vasodilator properties; possible mechanisms explaining
this effect are: stimulation of nitric oxide production, blockade
of Ca2+ entry, opening of K+ channels, and antioxidant activ-
ity. In particular, nebivolol has been demonstrated to activate
endothelial β3-AR, thus stimulating NO production and dilation
of coronary arteries (Rozec et al., 2006).
INTRINSIC SYMPATHOMIMETIC ACTIVITY (ISA)
Although classified as blockers, some molecules belonging to this
class can act as partial agonists, thus activating β1-AR. The intrin-
sic sympathomimetic activity of pindolol, acebutolol and celipro-
lol can improve BB tolerability, since they do not cause severe
bradycardia or excessive negative inotropic effects at rest. On the
other hand, some BB also act as inverse agonists, thus inducing a
negative response of receptor signaling in absence of the natural
agonist. This characteristic has clinical consequences, since drugs
as bucindol (with low inverse agonist activity) decrease mean and
peak heart rate, while they do not reduce minimum heart rate
(Wachter and Gilbert, 2012).
PHARMACOKINETICS
BB widely differ in their physico-chemical properties. In par-
ticular, lipophilic compounds such as metoprolol, bucindolol,
carvedilol and nebivolol, when given orally, are rapidly adsorbed
in the gastrintestical tract and are extensively metabolized by
the liver, therefore often presenting with a shorter half-life when
compared to other BB. Moreover, the high lipophilicity and the
resulting higher penetration across the blood-brain barrier could
also explain the increased number of brain-related adverse events,
as well as the membrane-stabilizing (quinidine-like) properties of
antiarrhythmic molecules which appear independent of their BB
activities (Murray et al., 1990).
OTHER PROPERTIES
Carvedilol and its metabolites are also endowed with antioxi-
dant activity, a property that can be useful in the treatment of
HF; propanolol and carvedilol seem to decrease vascular smooth
muscle cells proliferation. Moreover, carvedilol and bucindolol
canmodulate guanine-nucleotide binding to its receptor (Bristow
et al., 1992). It has been also demonstrated that carvedilol amelio-
rates insulin sensitivity (Jacob et al., 1996).
PHARMACOKINETICS
As stated before, lipophilicity is one of the chemical character-
istics influencing bioavailability and, consequently, administra-
tion schedule. High lipophilic molecules such as propanolol are
rapidly adsorbed but, at the same time, they become extensively
metabolized by the liver (first-pass metabolism); by contrast,
drugs with intermediate lipophilic properties (bisoprolol) are
efficiently adsorbed in the gut but poorly removed by the liver
first-pass metabolism, so that they display high bioavailability
(90%). Many BB are metabolized by the liver through the CYP
pathway, in particular via the CYP2D6 isoform; in humans, the
CYP2D6 enzyme is highly polymorphic and this characteristic
has been often referred to explain the inter-individual variabil-
ity observed in the plasma levels of drugs such as carvedilol
and in the responses to treatment with BB in HF. Other CYP
isoforms (CYP1A2, CYP2C9, CYP2C19 and CYP3A4) can con-
tribute, though to a lesser extent, to BB hepatic metabolism, while
other molecules, such as bisoprolol, are excreted unmodified via
the kidney. As a consequence, dose modification of BB should
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be considered in patients with pathological conditions impair-
ing both liver and kidney functions, or for patients treated also
with drugs metabolized by the same CYP isoforms (antidepres-
sants, antipsychotics). Moreover, it should be mentioned that
peak plasma concentrations, as well as half-lives, are strongly
influenced by the formulation of the molecule; this has impor-
tant consequences on clinical outcomes. A paradigmatic example
is represented by the two different formulations of metoprolol
used in controlled clinical trials; indeed, in the COMET study
(Carvedilol or Metoprolol European Trial), the reduced efficacy
demonstrated in the metoprolol-tartrate arm with respect to the
carvedilol arm has been largely explained by the shorter half-
life of metoprolol-tartrate when compared to carvedilol. It has
been suggested that this pharmacokinetic difference led to a dif-
ferent degree of beta blockade in patients enrolled in the two
study arms, and, therefore, that the dose of metoprolol tartate
administered in this study was inadequate (Poole-Wilson et al.,
2003). In a subsequent trial, MERIT-HF (Metoprolol CR/XL
Randomized Intervention Trial in Congestive Heart failure), a
different and longer-lasting formulation, metoprolol-succinate,
was demonstrated to reduce mortality and hospitalization in HF
patients (Hjalmarson et al., 2000); the degree of these protec-
tive effects were now similar to those demonstrated for other BB
with longer plasma half-lives. Based on these evidence, FDA has
approved metoprolol-succinate, but not metoprolol-tartrate, for
the treatment of patients with HF.
TOLERABILITY OF β-BLOCKERS
The most common adverse events of BB result from their mech-
anism of action. The blockade of sympathetic stimulation may
have both acute or chronic consequences, mainly giving rise to
symptoms of cardiovascular, respiratory, central nervous system
and metabolic origins.
In particular, acute blockade of catecholamines effects can
induce bradycardia that can be potentially life-threatening in
patients with defects in atrio-ventricular conduction; moreover,
acute blockade of β-ARs can worsen myocardial contractility and,
consequently, induce or deteriorate HF in patients with myocar-
dial infarction, cardiomegaly or compensated HF. Starting with
low doses and slowly titrating up (in order to reach the opti-
mal dose in several weeks) is a widely used and well known
strategy to reduce these risks. In the same vein, given that
a prolonged BB treatment may induce β-ARs up-regulation
and, consequently, an enhanced sensitivity to catecholamines,
abrupt withdrawal of BB should be avoided in order to pre-
vent angina and risk of sudden death. BB treatment can also
induce Raynaud’s phenomenon and worsen peripheral vascular
disease.
As β2-ARs-blockade cause bronchoconstriction, BB have been
considered as contraindicated in patients suffering from asthma
or Chronic Obstructive Pulmonary Disease (COPD). Thus, con-
cerns exist regarding the use of BB in patients with HF and COPD,
in particular for non-cardioselective molecules; however, the risk
to increase bronchoconstriction, thus worsening COPD symp-
toms, is often overcome by the beneficial effects on HF. For these
reasons, COPD is currently considered as a relative contraindi-
cation for BB treatment, and a careful risks-benefits assessment
should be made to avoid undertreatment of HF patients with
respiratory comorbidities (Ellison and Gandhi, 2005).
BB also impact glucose homeostasis, since catecholamines,
mainly through β2-AR, promote glycogenolysis and glucose-
mobilization in response to hypoglycemia, thus increasing blood
glucose levels. Therefore, BB can conceal symptoms of hypo-
glycemia or cause an excessive reduction of blood glucose in
susceptible diabetic patients treated with insulin or oral hypo-
glycemic agents. β1-AR selective antagonists, as well as carvedilol,
the latter shown to improve insulin-sensitivity, could possibly
represent a valid alternative for HF patients with concomitant
diabetes.
EFFICACY OF BB IN HF
The efficacy of BB in the treatment of HF has been evaluated in
several randomized, controlled clinical trials (Table 2). Patients
enrolled in these studies suffered from HF with different etiol-
ogy and showed an impaired systolic function. Taken together,
the aforementioned clinical trials have demonstrated that three
BB (metoprolol succinate, bisoprolol and carvedilol) are able to
improve ventricular ejection fraction and HF symptoms, and to
reduce mortality and hospitalizations. Of note, numerous trials
were prematurely discontinued for mostly ethical reasons, since
interim analysis showed a reduced mortality in the BB arm com-
pared to placebo-arm. Bucindolol and nebivolol have also been
tested in clinical trials, with different results.
METOPROLOL
Metoprolol has been one of the first BB to be studied in HF treat-
ment. 383 patients with systolic disfunction secondary to dilated
cardiomyopathy were randomized to placebo or metoprolol at a
target dose of 100–150mg/daily. Metoprolol was shown to reduce
mortality and need of transplantations by 34% with respect to
placebo arm (Waagstein et al., 1993). A subsequent wider trial
(3991 patients in 14 countries), MERIT-HF, investigated the effi-
cacy of metoprolol succinate in mild-moderate HF patients with
impaired systolic function (left ventricular ejection fraction-LVEF
<40%) andNew YorkHeart Association (NYHA) functional class
II–IV; in this study, a long-lasting release metoprolol formulation
was used, with a mean daily dose of 159mg (Hjalmarson et al.,
2000). The authors found a 34% statistically-significant decrease
in mortality and a reduction in combined endpoint “all-cause
mortality and hospitalization” (risk reduction by 19%); the bene-
ficial effects of metoprolol were even higher on cardiac death and
non-fatal acute myocardial infarction, with a 39% risk reduction.
BISOPROLOL
Following a previous Cardiac Insufficiency Bisoprolol Study
(CIBIS), in which bisoprolol administration showed a non-
statistically significant trend toward improved survival in HF
patients (1994), a subsequent CIBIS-II trial enrolled a higher
number of subjects (n = 2647) with LVEF <35% and NYHA
class III–IV. As for metoprolol, a reduction in all-cause mortality
was demonstrated for bisoprolol-treated patients when compared
to placebo-arm (11.8 vs. 17.3%, respectively), with a follow-up
of about 1 year (1999). More recently, a third study with biso-
prolol (CIBIS III) has addressed the relevant issue of whether
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Table 2 | Summary of main clinical trials reported in the text investigating the efficacy of BB in HF.
Study name (reference) No patients BB used Description Main findings Additional findings and
comments
MDC (Waagstein et al.,
1993)
383 Metoprolol HF secondary to
Dilated Cardiomyopathy
(EF <40%)
34% decrease in mortality
or need for transplantation
No significant
difference in mortality alone
MERIT-HF (Hjalmarson
et al., 2000)
3991 Metoprolol
succinate
Mild-moderate HF (EF
<40%)
NYHA II-IV
<34% decrease in all cause
mortality
<39% decrease in cardiac
death and non-fatal MI
CIBIS (CIBIS
Investigators and
Committees, 1994)
641 Bisoprolol Moderate HF
(EF <40%)
NYHA III-IV
No significant difference in
mortality
Significant improvement of
functional status of the
patients
CIBIS II (CIBIS-II
Investigators, 1999)
2647 Bisoprolol Moderate HF (EF
<35%) NYHA III-IV
32% decrease
risk of mortality and
hospitalization for HF
Greatest effects in patients
with ischaemic HF
and NYHA III at baseline
CIBIS III (Willenheimer
et al., 2005)
1010 Bisoprolol
(vs. enalapril)
Mild moderate HF
(EF <35%)
NYHA II-III
Non-inferiority of bisoprolol
vs enalapril in reducing
mortality as first treatment
in ITT
Non-inferiority of bisoprolol
was not proven in
per-protocol analysis
US Carvedilol study
(Packer et al., 1996)
1094 Carvedilol Mild moderate HF
NYHA II-IV
65% mortality reduction 38% reduction in death or
hospitalization for
cardiovascular reasons
COPERNICUS (Packer
et al., 2002)
2289 Carvedilol Severe HF
(EF <25%)
NYHA III-IV
35% in risk of death 27% decrease death or
hospitalization for a
cardiovascular reason
CAPRICORN (The
CAPRICORN
Investigators, 2001)
1959 Carvedilol Patients with recent MI
and left ventricular
dysfunction (EF <40%)
23% reduction in mortality No significant difference in
primary endpoint (all-cause
mortality or hospitalization
for cardiovascular problems)
COMET (Poole-Wilson
et al., 2003)
3029 Carvedilol vs.
Metoprolol
tartrate
Mild moderate HF
(EF <35%)
NYHA II-IV
17% decrease in carvedilol-
vs. metoprolol- arm
Concerns about metoprolol
formulation
BEST (BEST
Investigators, 2001)
2708 Bucindolol Mild moderate HF
(EF <35%)
NYHA III-IV
No significant overall
survival
benefit
Reduction in mortality in
patients homozygous for
Arg389 (subsequent
pharmacogenetic analysis)
SENIORS (Flather et al.,
2005)
2128 Nebivolol Mild moderate HF
(EF <35% in last
6-months)
Age >70yrs
14% reduction mortality
and hospitalizations
Significant
increase of
LVEF and decrease in
end-systolic volume
The Table re-elaborates and integrates the data reported in Table I of Kubon et al., 2011.
BB could be as effective as renin-angiotensin-aldosterone system
(RAAS) inhibitors as first-line drugs in HF. In general, therapy
in CHF patients is initiated with an ACE inhibitor or an AngII-
receptor blocker (ARB), and thereafter a β-blocker is introduced.
This drug sequence seems to result largely from the fact that,
historically, the beneficial effects of ACE inhibitors were docu-
mented first. The order of initiation of these agents is of great
relevance, because the first agent initiated is more likely to be
titrated up to its target dose, whereas the second agent is often
given at a suboptimal dose or not initiated at all. Theoretically,
sympathetic system alterations occur before RAAS dysfunction
during chronic HF; moreover, it is well known that stimulation
of β1-ARs in iuxtaglomerular cells can increase renin produc-
tion, thus contributing to RAAS over activation. The CIBIS III
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trial compared bisoprolol to enalapril, one of the most used
first-line drug for HF. Patients with LVEF <35% were random-
ized to bisoprolol- or enalapril; after a 6-months mono-therapy
period, patients received both drugs. The results obtained showed
the non-inferiority of bisoprolol-first versus enalapril-first strat-
egy, in the Intention to treat population but not in per-protocol
analysis, thus requiring more data to better clarify this issue
(Willenheimer et al., 2005).
CARVEDILOL
This non-selective, third generation BB has been tested in dif-
ferent trials. The first randomized study evaluated the efficacy
of carvedilol on 1094 US patients with LVEF <35%, strati-
fied according to their performance on exercise tests. Carvedilol
was shown to reduce mortality risk by 65% when compared to
placebo; these data induced the Monitoring Board to terminate
the study before its scheduled completion (Packer et al., 1996).
The efficacy of carvedilol has been evaluated also in patients
with severe HF, a group often not included in randomized trials.
The COPERNICUS study enrolled 2289 patients with symptoms
of HF at rest or on minimal exertion and with LVEF <25%,
randomized to carvedilol or placebo; in the carvedilol arm, a
reduction by 35% in the risk of death and an improvement in
HF symptoms were observed (Packer et al., 2002). Carvedilol has
been evaluated also in patients with left ventricular dysfunction,
with or without HF, secondary to myocardial infarction. The aim
of the CAPRICORN study was to evaluate whether addition of
carvedilol to standard modern management of acute myocar-
dial infarction would improve outcome in terms of mortality
and morbidity. The results obtained confirmed that carvedilol
decreased the risk of mortality by 23%when compared to placebo
(2001).
It should be mentioned that clinical trials have investigated
efficacy of BB in patients with impaired LVEF (<40%); however,
since BB lower myocardial work by reducing heart rate and oxy-
gen demand, it seems desirable to extend these studies also to
HF patients with preserved systolic ejection fraction such as the
elderly population.
COMPARISON BETWEEN BB
Collectively, results emerged from clinical trials demonstrated
that blockade of β-AR signaling has beneficial effects in HF, both
reducing mortality and improving symptoms of impaired cardiac
function. Such protection has been demonstrated for different
molecules belonging to BB class, and the degree of the benefi-
cial effects was quite similar for any of the chosen drug. Thus,
the possibility existed that BB efficacy in HF was due to a “class
effect.” On the other hand, many researchers have pointed out
that peculiar pharmacodynamic and/or pharmacokinetic proper-
ties (β1-AR-selectivity, vasodilating actions, anti-oxidant activity,
“pleiotropic effects”, good bioavailability, low drug-drug interac-
tion risk) could represent valuable characteristics for preferring a
specific molecule over other BBs in the treatment of HF. To ver-
ify this hypothesis, a specific clinical trial was conducted in 2003.
The COMET study aimed to compare the mortality risk-reducing
effects in 3029 patients with HF randomized to receive either
carvedilol or metoprolol, after a mean follow-up of 58 months.
The results demonstrated that carvedilol decreased mortality by
17% with respect to metoprolol (Poole-Wilson et al., 2003); how-
ever, as mentioned before, subsequent analyses showed that the
degree of β-blockade reached with the formulation of metopro-
lol used in the study (metoprolol tartrate) was not adequate, and
probably not similar to that of the carvedilol arm. Basically, meto-
prolol tartrate should have been titrated up in the COMET study
(Talber, 2004).
A solution to this issue has been also pursued by several meta-
analyses; most of these have been focused on carvedilol, possibly
because of its unique pharmacodynamic profile. Nevertheless,
results from these studies seem to be conflicting; in a system-
atic review of 11 randomized controlled trials in 5,207 patients, it
was found that carvedilol reduced all-cause mortality in patients
with HF significantly more when compared to other BB such as
atenolol, bisoprolol and metoprolol. According to the Authors,
the superiority of carvedilol over other BB could be explained by
the peculiar actions exerted by carvedilol, such as: antiarrhyth-
mic effect (and consequent reduction in the risk of sudden death),
a more sustained increase in LVEF when compared to other BB,
blockade of up-regulated β2-AR, vasodilation. (DiNicolantonio
et al., 2013). By contrast, in their meta-analysis of 21 trials
including 23122 HF patients, Chatterjee et al. found no signif-
icant differences in mortality outcome among the BB consid-
ered (atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and
nebivolol), thus concluding that the beneficial of BB were due
to a class effect. Nonetheless, carvedilol showed the lowest car-
diac mortality among all β blockers tested, although this was
not statistically significant; in consideration also of the its ben-
eficial effects on lipid and glucose profile, the Authors suggest the
use of carvedilol as an empiric initial treatment in patients with
cardiovascular comorbidities (Chatterjee et al., 2013).
Lack of clear data from clinical trials regarding the superiority
of a given BB are reflected in current guidelines for the manage-
ment of HF, in which the use of a particular BB over the others is
not specified.
PHARMACOGENOMICS OF BB
As for many other pharmacological treatments, variability in clin-
ical and functional outcomes exists also for BB administration in
HF patients. Actually, BB treatment fails to improve LVEF in a
variable proportion of subjects, while a minority of patients expe-
rience worsening of HF symptoms during BB titration (Talameh
et al., 2012); such differences could be explained, at least in part,
by genetic variation influencing BB pharmacodynamics and/or
pharmacokinetics. To date, polymorphisms in β1-AR, β2-AR,
GRK-5, CYP2C6, NET and UGT1A1 have been associated to
variability in BB response.
β1-AR
The most studied polymorphism in the β1-AR gene (ADRB1) is
the Arg389Gly. β1-ARs possessing arginine residue show greater
activity, both in basal condition and after agonist-stimulation.
Therefore, in these patients, β-blockade might potentially have a
greater effect by reducing the high sympathetic stimulation deter-
mined by the β1-Arg receptor (Talameh and Lanfear, 2012). On
the other hand, the high sympathetic activity could require higher
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dose of BB. The most convincing result from the literature con-
cerning the possible role of Arg389Gly variant in BB treatment
comes from BEST study, a trial investigating the effects of bucin-
dolol in HF. Despite the main study failed to demonstrate the
efficacy of bucindolol in all the population studied, subsequent
pharmacogenetic analysis clearly demonstrated that bucindolol
significantly reduced mortality when compared to placebo in
patients homozygous for Arg389 (2001). Nevertheless, different
studies, such as the pharmacogenetic sub-study of MERIT-HF,
failed to find association between Arg389 allele andmortality out-
come, suggesting that results from BEST depended on bucindolol
peculiar properties (in particular to its marked ability to suppress
β1-ARs), and could not be extended to other BB.
Another pharmacogenetic sub-study, the HF-ACTION DNA,
demonstrated that patients with the Arg/Arg genotype required a
higher dose of BB to achieve a mortality risk reduction similar to
that of Gly carriers (Fiuzat et al., 2013).
Another variant of ADRB1, Ser49Gly, has been associated to
differential outcome in HF and response to β-AR antagonists.
The presence of the glycine residue is thought to enhance agonist-
promoted down-regulation of β1-AR with respect to Ser49 (Levin
et al., 2002), thus preserving failing myocardium from toxic
effects exerted by catecholamines. However, data about its pos-
sible role in determining BB response are poor and inconsistent.
β2-AR
As stated before, β2-AR signaling plays a more relevant role in
the failing heart, since β1-AR expression is down-regulated. Thus,
variants in ADRB2 gene could modulate response to BB treat-
ment. Among the three polymorphisms identified in β2-AR gene,
Gln27Glu variation has been investigated; Glu27 β2-AR shows
an enhanced resistance to desensitization. Results from clinical
trials are conflicting: some studies found a lower proportion of
responders to BB treatment for patients homozygous for Gln27,
other trials failed to find associations. However, these negative
data could be explained by the reduced number of participants
and by the inclusion of β1-AR-selective blocker (Talameh et al.,
2012).
α2C-AR AND GRK-5
Genetic variants of the presynaptic α2 receptor and of the
G-protein coupled receptor kinase-5 seem to contribute to the
variability in BB response. In particular, association of polymor-
phisms of α2C-AR and GRK-5 with the Arg389 variant in β1-AR
might impact response to BB. Indeed, a variant of the α2C-AR
gene leading to a deletion of amino acids 322–325, which resulted
in an increase of catecholamine stimulation, when associated to
the Arg389 variant in the ADRB1, caused a more pronounced
increase in LVEF with respect to other genotypes. In the same
way, patients with the Gln41variant in GRK5 and Arg389 in β1-
AR showed advantages in term of reduced mortality after BB
treatment (Talameh et al., 2012).
CYP2D6 AND UGT1A
As mentioned before, CYP2D6 is the main CYP isoform involved
in BB metabolism. Thus, genetic variants in this gene have been
suggested to modulate BB response. In the same vein, poly-
morphisms in UGT1A1 have been also proposed to modify
BB metabolism and, consequently, response to pharmacological
treatment. The study of (Baudhuin et al., 2010) retrospec-
tively analyzed 93 patients characterized as responders or non-
responders to metoprolol or carvedilol therapy. These patients
have been also classified according to their genotype in differ-
ent classes, ranging from poor to extensive metabolizer, for both
CYP2D6 and UGT1A1 variants. The Authors did not find any
association between CYP2D6 and UGT1A1 polymorphisms and
response to therapy with carvedilol or metoprolol; neverthe-
less, patients who were poor metabolizer for CYP2D6 required
a higher dose of carvedilol. These data might be relevant in
patients also carrying ADRB1 Gly/Gly variant, since higher dose
of carvedilol should be used to reach beneficial effects on HF
(Baudhuin et al., 2010).
Taken together, these results, although suggestive of the pos-
sibility to select BB according to a particular genotype, are not
conclusive, thus requiring large prospective clinical trials.
BB IN SPECIFIC GROUP OF PATIENTS
Although their efficacy in HF has been demonstrated, BB are
not given or are inadequately administered to some categories
of patients. Among them, elderly patients are frequently under-
treated, because of comorbidities, reduced tolerability to BB,
and risk to worsen symptoms of HF. Moreover, elderly patients
frequently show preserved LVEF, thus making even harder the
decision to start BB therapy. Nevertheless, analysis of randomized
trials have shown that BB reduce mortality and improve qual-
ity of life also in patients >70 years, as well as in younger ones.
Among BB, nebivolol has been considered as the most interest-
ing for HF in elderly because of its unique pharmacodynamic
profile. Indeed, the β1-AR-selective antagonist nebivolol is not
provided with vasoconstrictor activity and should not interfere
with respiratory function; moreover, stimulation of NO release
might improve diastolic function. These characteristics might
be relevant in elderly patients, frequently showing comorbidities
and commonly less tolerant to peripheral vasoconstriction (Del
Sindaco et al., 2010). Based on these evidence, two clinical trials
have investigated efficacy of nebivolol in aged HF patients. While
the ENECA study demonstrated an improvement in LVEF in
patients >65 years (Edes et al., 2005), the SENIORS trial showed
that nebivolol reducemortality and hospitalizations by 14%when
compared to placebo. Nebivolol was also well tolerated, includ-
ing in patients with impaired renal function, and the proportion
of patients discontinuing treatment due to adverse events was
similar in nebivolol and placebo arms (Flather et al., 2005).
As stated before, COPD is considered a contraindication to
BB treatment because of the risk to induce bronchoconstric-
tion, thus worsening symptoms. To this aim, cardioselective BB
have been proposed to overcome the possible lack of tolerabil-
ity by HF patients with concomitant COPD. A recent analysis by
Mentz et al. has compared β1-selective versus non-selective drugs
in determining worse outcomes in HF patients enrolled in the
OPTIMIZE-HF trial. The Authors found no evidence that car-
dioselectivity was associated with better outcomes, in terms of
both mortality and tolerability. The Authors also suggest that use
of non-selective BB might be helpful for HF (antagonism on β2-
AR, whose signaling has a relevant role in the failing heart) and
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COPD (reduction of pulmonary desensitization caused by β2-
agonists). These data support the hypothesis that BB might be
safe and well tolerated also in patients with HF and COPD (Mentz
et al., 2013).
CONCLUSIONS
BB use is strongly recommended in all current guidelines for
patient with symptomatic HF and impaired systolic function,
unless there is a contraindication. Although wide, random-
ized, controlled clinical trials have investigated efficacy of three
molecules, thus driving to the registration of carvedilol, metopro-
lol succinate and bisoprolol for the treatment of HF, it appears
reasonable to suppose that BB efficacy lies in their ability to
counteract adrenergic overactivation, more than in additional,
molecule-related properties. Such consideration is supported by
different meta-analyses suggesting that BB efficacy should be
considered as a class effect. However, peculiar mechanisms of
action of distinct BB (i.e., vasodilation, NO release, anti-oxidant
activity, anti-proliferant actions on vascular smooth muscle cells)
might represent additional and useful tools for HF therapy and
to increase treatment tolerability, mainly in selected groups of
patients such as elderly; a careful evaluation of the patient and
his clinical condition should be made. For instance, molecules
such as carvedilol, which have been demonstrated to ameliorate
insulin sensitivity, could be useful in patients with concomitant
diabetes. Moreover, analysis of genetic polymorphisms in β-ARs
and metabolic enzymes, might also contribute to find “the best
drug to the best patient.”
In conclusion, BB are currently a cornerstone in HF ther-
apy, and their use should be extended also to groups of patients
commonly undertreated, such as elderly or comorbid patients.
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